Cargando…

Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting

Radioactive(131) iodine (RAI) body burden is estimated in thyroid cancer patients by a) exposure rate meter and b) external probe counting. A calibration factor of 301 cpm/MBq (d = 16 cm) is used for the probe for estimates of whole body activity. Patients sit in a rotating stool with their center c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravichandran, Ramamoorthy, Al Balushi, Naima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020787/
https://www.ncbi.nlm.nih.gov/pubmed/27651735
http://dx.doi.org/10.4103/1450-1147.174701
_version_ 1782453265302028288
author Ravichandran, Ramamoorthy
Al Balushi, Naima
author_facet Ravichandran, Ramamoorthy
Al Balushi, Naima
author_sort Ravichandran, Ramamoorthy
collection PubMed
description Radioactive(131) iodine (RAI) body burden is estimated in thyroid cancer patients by a) exposure rate meter and b) external probe counting. A calibration factor of 301 cpm/MBq (d = 16 cm) is used for the probe for estimates of whole body activity. Patients sit in a rotating stool with their center corresponding to the field of view for estimation of whole body RAI. Radioactive counts are obtained for anterio posterior (AP) and postero anterior (PA) geometries. Whole body retention factor is expressed as a ratio against assayed activity administered to the patient on day 1. With exposure rate measurement, for off-thyroxin (hypothyriod) patients, the retention factors were 0.148 ± 0.12 (n = 211) and 0.07 ± 0.08 (n = 68) at 48 h and 72 h, respectively. For recombinant TSH (rhTSH) (euthyroid) group, the retention factors were 0.089 ± 0.06 (n = 24) and 0.05 ± 0.05 (n = 19) at 48 h and 72 h, respectively. By probe counting method, the obtained retention factors were 0.081 ± 0.013 (range: 0.071–0.096) (off-thyroxine group) and 0.039 ± 0.03 (range: 0.008–0.089) for the rhTSH group at 48 h. The 72 h retentions in the off thyroxine (hypothyriod) group and the rhTSH (euthyroid) group were 0.048 ± 0.024 (range: 0.016–0.076) and 0.005, respectively. The radioactive body burdens at 48 h were in the range of 290-315 MBq (7.8–8.5 mCi) for the off-thyroxine group and 44–286 MBq (1.2–7.7 mCi) for the rhTSH group. The calculated residence times in whole body were 21.97 ± 3.8 h (range: 17.1–27.1) for off-thyroxine group and 14.28 ± 2.75 h (range: 9.97-19.46) showing high statistical significance (P < 0.001). The specific blood doses were 0.118 ± 0.025 mGy/MBq (range: 0.083–0.172) for the off-thyroxine group (females n = 23); 0.87 ± 0.028 mGy/MBq (range: 0.057–0.130) (females n = 13), 0.080 ± 0.013 mGy/MBq (range: 0.069–0.098) (males n = 5) and 0.080 ± 0.028 (range: 0.059–0.118 for rhTSH patients (males n = 4). The mean mGy/MBq for blood was higher in females—about 10% for the rhTSH group compared to 40% higher for the off thyroxine (THW) group. The dose to blood was “inversely proportional” to the body weight, both in the off-thyroxine group and the rhTSH group but the dependence was not very strong with rhTSH administration because of less residence time of the radioactive iodine. There was no correlation between administered activity and retained body burden at 48 h or 72 h.
format Online
Article
Text
id pubmed-5020787
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-50207872016-09-20 Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting Ravichandran, Ramamoorthy Al Balushi, Naima World J Nucl Med Original Article Radioactive(131) iodine (RAI) body burden is estimated in thyroid cancer patients by a) exposure rate meter and b) external probe counting. A calibration factor of 301 cpm/MBq (d = 16 cm) is used for the probe for estimates of whole body activity. Patients sit in a rotating stool with their center corresponding to the field of view for estimation of whole body RAI. Radioactive counts are obtained for anterio posterior (AP) and postero anterior (PA) geometries. Whole body retention factor is expressed as a ratio against assayed activity administered to the patient on day 1. With exposure rate measurement, for off-thyroxin (hypothyriod) patients, the retention factors were 0.148 ± 0.12 (n = 211) and 0.07 ± 0.08 (n = 68) at 48 h and 72 h, respectively. For recombinant TSH (rhTSH) (euthyroid) group, the retention factors were 0.089 ± 0.06 (n = 24) and 0.05 ± 0.05 (n = 19) at 48 h and 72 h, respectively. By probe counting method, the obtained retention factors were 0.081 ± 0.013 (range: 0.071–0.096) (off-thyroxine group) and 0.039 ± 0.03 (range: 0.008–0.089) for the rhTSH group at 48 h. The 72 h retentions in the off thyroxine (hypothyriod) group and the rhTSH (euthyroid) group were 0.048 ± 0.024 (range: 0.016–0.076) and 0.005, respectively. The radioactive body burdens at 48 h were in the range of 290-315 MBq (7.8–8.5 mCi) for the off-thyroxine group and 44–286 MBq (1.2–7.7 mCi) for the rhTSH group. The calculated residence times in whole body were 21.97 ± 3.8 h (range: 17.1–27.1) for off-thyroxine group and 14.28 ± 2.75 h (range: 9.97-19.46) showing high statistical significance (P < 0.001). The specific blood doses were 0.118 ± 0.025 mGy/MBq (range: 0.083–0.172) for the off-thyroxine group (females n = 23); 0.87 ± 0.028 mGy/MBq (range: 0.057–0.130) (females n = 13), 0.080 ± 0.013 mGy/MBq (range: 0.069–0.098) (males n = 5) and 0.080 ± 0.028 (range: 0.059–0.118 for rhTSH patients (males n = 4). The mean mGy/MBq for blood was higher in females—about 10% for the rhTSH group compared to 40% higher for the off thyroxine (THW) group. The dose to blood was “inversely proportional” to the body weight, both in the off-thyroxine group and the rhTSH group but the dependence was not very strong with rhTSH administration because of less residence time of the radioactive iodine. There was no correlation between administered activity and retained body burden at 48 h or 72 h. Medknow Publications & Media Pvt Ltd 2016-09 /pmc/articles/PMC5020787/ /pubmed/27651735 http://dx.doi.org/10.4103/1450-1147.174701 Text en Copyright: © World Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Ravichandran, Ramamoorthy
Al Balushi, Naima
Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting
title Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting
title_full Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting
title_fullStr Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting
title_full_unstemmed Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting
title_short Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting
title_sort radioactive (131)iodine body burden and blood dose estimates in treatment for differentiated thyroid cancer by external probe counting
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020787/
https://www.ncbi.nlm.nih.gov/pubmed/27651735
http://dx.doi.org/10.4103/1450-1147.174701
work_keys_str_mv AT ravichandranramamoorthy radioactive131iodinebodyburdenandblooddoseestimatesintreatmentfordifferentiatedthyroidcancerbyexternalprobecounting
AT albalushinaima radioactive131iodinebodyburdenandblooddoseestimatesintreatmentfordifferentiatedthyroidcancerbyexternalprobecounting